Integer (NYSE:ITGR – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided EPS guidance of 5.010-5.430 for the period, compared to the consensus EPS estimate of 5.310. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion. Integer also updated its FY24 guidance to $5.01-5.43 EPS.
Analyst Upgrades and Downgrades
ITGR has been the subject of several research reports. CL King began coverage on Integer in a report on Thursday, March 14th. They issued a buy rating and a $137.00 target price for the company. Benchmark reaffirmed a buy rating and set a $130.00 price target on shares of Integer in a research report on Friday. Bank of America raised Integer from a neutral rating to a buy rating and increased their price objective for the company from $105.00 to $135.00 in a report on Monday, April 15th. Finally, KeyCorp upped their price target on shares of Integer from $123.00 to $139.00 and gave the company an overweight rating in a research report on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $120.50.
Check Out Our Latest Report on Integer
Integer Stock Performance
Integer (NYSE:ITGR – Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.02. The firm had revenue of $414.80 million during the quarter, compared to analysts’ expectations of $412.78 million. Integer had a return on equity of 10.80% and a net margin of 5.68%. Integer’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.87 earnings per share. On average, research analysts expect that Integer will post 5.31 EPS for the current year.
Integer Company Profile
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Featured Stories
- Five stocks we like better than Integer
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Are Trending Stocks? Trending Stocks Explained
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.